Anhydrovinblastine for the treatment of cancer
    1.
    发明授权
    Anhydrovinblastine for the treatment of cancer 失效
    用于治疗癌症的脱氢长春花碱

    公开(公告)号:US06326376B1

    公开(公告)日:2001-12-04

    申请号:US09380540

    申请日:2000-01-21

    IPC分类号: A61K3144

    CPC分类号: A61K31/475

    摘要: The present invention is particularly directed to the use of a derivative of vinblastine, 3′,4′-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3′,4′ position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an anti-neoplastic agent in the therapeutic treatment of cancer.

    摘要翻译: 本发明特别涉及长春碱,3',4'-脱氢长春碱(AHVB)的衍生物,其与长春花碱不同,因为它在黄嘌呤核的3',4'位具有双键,而不是 比在母体结构中存在的羟基作为癌症治疗性治疗中的抗肿瘤剂。

    Use of anhydrovinblastine
    2.
    发明授权
    Use of anhydrovinblastine 失效
    使用脱氢长春花碱

    公开(公告)号:US6011041A

    公开(公告)日:2000-01-04

    申请号:US690195

    申请日:1996-07-26

    CPC分类号: C07D519/04 Y10S514/908

    摘要: The present invention is particularly directed to the use of a derivative of vinblastine, 3',4'-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3',4' position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an antineoplastic agent in the therapeutic treatment of cancer. Specifically, the treatment of lymphoma with 3',4'-anhydrovinblastine is disclosed.

    摘要翻译: 本发明特别涉及长春碱,3',4'-脱氢长春碱(AHVB)的衍生物,其与长春花碱不同,因为它在黄嘌呤核的3',4'位具有双键,而不是 比在母体结构中存在的羟基作为癌症治疗性治疗中的抗肿瘤剂。 具体地,公开了用3',4'-脱氢长春花碱治疗淋巴瘤。

    Methods to individualize combination therapy
    10.
    发明申请
    Methods to individualize combination therapy 审中-公开
    个性化联合治疗方法

    公开(公告)号:US20060228694A1

    公开(公告)日:2006-10-12

    申请号:US10551374

    申请日:2004-04-02

    IPC分类号: A61K38/17 C12Q1/00 C12Q1/68

    摘要: Compositions which comprise delivery vehicles having stably associated therewith predetermined, patient-specific combinations of two or more agents, such as antineoplastic agents, are useful in achieving optimal therapeutic effects on a patient-by-patient basis when combinations of drugs are administered.

    摘要翻译: 包含递送载体的组合物,当两种或更多种药物如抗肿瘤药物的预定的患者特异性组合具有稳定相关性时,可用于在施用药物组合时实现逐个患者的最佳治疗效果。